CASI Pharmaceuticals, Inc. has signed an agreement for exclusive worldwide license and commercialization rights to an autologous anti-CD19 T-cell therapy product (CNCT19) from Juventas Cell Therapy Ltd., based in Tianjin City, China. Juventas will continue to develop CNCT19 with CASI’s participation on the program’s steering committee. CASI will be responsible for payment of certain future development milestones and sales royalties. In connection with the license, CASI Pharmaceuti...